{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:12:34Z","timestamp":1785247954507,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study aims to assess the efficacy and safety of Qingpeng ointment (QPO), a Tibetan medicine for alleviating symptoms in individuals with acute gouty arthritis (AGA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study was a randomized, double-blind, placebo-controlled trial that involved individuals with AGA whose joint pain, as measured on a visual analog scale (VAS) from 0 to 10, was equal to or greater than 3. The participants were randomly assigned to either the QPO or the placebo group and received their respective treatments twice daily for seven consecutive days. In case of intolerable pain, the participants were allowed to use diclofenac sodium sustained-release tablets as a rescue medicine. The primary outcomes measured were joint pain and swelling, while the secondary outcomes included joint mobility, redness, serum uric acid levels, C-reactive protein levels, and the amount of remaining rescue medicine. Any adverse events that occurred during the trial were also recorded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 203 cases were divided into two groups, with balanced baselines: 102 in the QPO group and 101 in the placebo group. For joint pain, differences between the groups were notable in the VAS scores [1.75 (0, 3.00) versus 2.00 (1.00, 3.50); <jats:italic>P<\/jats:italic>\u2009=\u20090.038], changes in VAS [5.00 (3.00, 6.00) versus 4.00 (2.00, 6.00); <jats:italic>P<\/jats:italic>\u2009=\u20090.036], and disappearance rate [26.47% compared to 15.84%; <jats:italic>P<\/jats:italic>\u2009=\u20090.046] after treatment. Concerning joint swelling, significant between-group differences were observed in the VAS scores [1.00 (0, 2.30) versus 2.00 (0.70, 3.00); <jats:italic>P<\/jats:italic>\u2009=\u20090.032] and disappearance rate [33.33% compared to 21.78%; <jats:italic>P<\/jats:italic>\u2009=\u20090.046] at treatment completion. The QPO group exhibited a statistically significant mobility improvement compared to the placebo group (<jats:italic>P<\/jats:italic>\u2009=\u20090.004). No significant differences were found in other secondary outcomes. Five patients, four from the QPO group and one from the other, encountered mild adverse events, primarily skin irritation. All of these cases were resolved after dosage reduction or discontinuation of the medication.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Compared to the placebo, QPO exhibits positive effects on AGA by alleviating pain, reducing swelling, and enhancing joint mobility, without causing significant adverse effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial Registration<\/jats:title>\n                <jats:p>ISRCTN34355813. Registered on 25\/01\/2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12906-023-04328-7","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T13:03:02Z","timestamp":1704373382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of Qingpeng ointment (a Tibetan medicine) for acute gouty arthritis: a multi-center, randomized, double-blind, placebo-controlled trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Ya-xi","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-feng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-peng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-chang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-min","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru-lu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-na","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu-zhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-xian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-yong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-guo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-li","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-e","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-fen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-lian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-qian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-ping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-dan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-chun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"4328_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.04.008","author":"JA Singh","year":"2020","unstructured":"Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.04.008","journal-title":"Semin Arthritis Rheum"},{"key":"4328_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep086","author":"M Doherty","year":"2009","unstructured":"Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford). 2009. https:\/\/doi.org\/10.1093\/rheumatology\/kep086","journal-title":"Rheumatology (Oxford)"},{"key":"4328_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/762820","author":"R Liu","year":"2015","unstructured":"Liu R, Han C, Wu D, Xia X, Gu J, Guan H, et al. Prevalence of Hyperuricemia and gout in Mainland China from 2000 to 2014: a systematic review and Meta-analysis. Biomed Res Int. 2015. https:\/\/doi.org\/10.1155\/2015\/762820","journal-title":"Biomed Res Int"},{"key":"4328_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2012.02794.x","author":"PC Robinson","year":"2012","unstructured":"Robinson PC, Taylor WJ, Merriman TR. Systematic review of the prevalence of gout and hyperuricaemia in Australia. Intern Med J. 2012. https:\/\/doi.org\/10.1111\/j.1445-5994.2012.02794.x","journal-title":"Intern Med J"},{"key":"4328_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22660","author":"T Bardin","year":"2016","unstructured":"Bardin T, Bou\u00e9e S, Clerson P, Chal\u00e8s G, Flipo RM, Liot\u00e9 F, et al. Prevalence of gout in the Adult Population of France. Arthritis Care Res (Hoboken). 2016. https:\/\/doi.org\/10.1002\/acr.22660","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4328_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.08.006","author":"SK Rai","year":"2017","unstructured":"Rai SK, Avi\u00f1a-Zubieta JA, McCormick N, De Vera MA, Shojania K, Sayre EC, et al. The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012. Semin Arthritis Rheum. 2017. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.08.006","journal-title":"Semin Arthritis Rheum"},{"key":"4328_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/art.40807","author":"M Chen-Xu","year":"2019","unstructured":"Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and Hyperuricemia in the United States and Decadal trends: the National Health and Nutrition Examination Survey, 2007\u20132016. Arthritis Rheumatol. 2019. https:\/\/doi.org\/10.1002\/art.40807","journal-title":"Arthritis Rheumatol"},{"key":"4328_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/art.41404","author":"S Safiri","year":"2020","unstructured":"Safiri S, Kolahi AA, Cross M, Carson-Chahhoud K, Hoy D, Almasi-Hashiani A, et al. Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors for 195 countries and territories 1990\u20132017: a systematic analysis of the global burden of Disease Study 2017. Arthritis Rheumatol. 2020. https:\/\/doi.org\/10.1002\/art.41404","journal-title":"Arthritis Rheumatol"},{"key":"4328_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket265","author":"P Chandratre","year":"2013","unstructured":"Chandratre P, Roddy E, Clarson L, Richardson J, Hider SL, Mallen CD. Health-related quality of life in gout: a systematic review. Rheumatology (Oxford). 2013. https:\/\/doi.org\/10.1093\/rheumatology\/ket265","journal-title":"Rheumatology (Oxford)"},{"key":"4328_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/art.41247","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the management of gout. Arthritis Rheumatol. 2020. https:\/\/doi.org\/10.1002\/art.41247","journal-title":"Arthritis Rheumatol"},{"key":"4328_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209707","journal-title":"Ann Rheum Dis"},{"key":"4328_CR12","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1000-6699.2020.01.001","author":"Chinese Society of Endocrinology, Chinese Medical Association","year":"2020","unstructured":"Chinese Society of Endocrinology, Chinese Medical Association. Guideline for the diagnosis and management of hyperuricemia and gout in China. Chin J Endocrinol Metab. 2020. https:\/\/doi.org\/10.3760\/cma.j.issn.1000-6699.2020.01.001","journal-title":"Chin J Endocrinol Metab"},{"key":"4328_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-2120-7","author":"S Stewart","year":"2020","unstructured":"Stewart S, Yang KCK, Atkins K, Dalbeth N, Robinson PC. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2020. https:\/\/doi.org\/10.1186\/s13075-020-2120-7","journal-title":"Arthritis Res Ther"},{"key":"4328_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.11.007","author":"\u00c1 Lanas","year":"2015","unstructured":"Lanas \u00c1, Carrera-Lasfuentes P, Arguedas Y, Garc\u00eda S, Bujanda L, Calvet X, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory Drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 2015. https:\/\/doi.org\/10.1016\/j.cgh.2014.11.007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4328_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014603","author":"R Costello","year":"2017","unstructured":"Costello R, Patel R, Humphreys J, McBeth J, Dixon WG. Patient perceptions of glucocorticoid side effects: a cross-sectional survey of users in an online health community. BMJ Open. 2017. https:\/\/doi.org\/10.1136\/bmjopen-2016-014603","journal-title":"BMJ Open"},{"key":"4328_CR16","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.12.005","author":"C Huerta","year":"2005","unstructured":"Huerta C, Castellsague J, Varas-Lorenzo C, Garc\u00eda Rodr\u00edguez LA. Nonsteroidal anti-inflammatory Drugs and risk of ARF in the general population. Am J Kidney Dis. 2005. https:\/\/doi.org\/10.1053\/j.ajkd.2004.12.005","journal-title":"Am J Kidney Dis"},{"key":"4328_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.09.012","author":"RT Keenan","year":"2011","unstructured":"Keenan RT, O\u2019Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011. https:\/\/doi.org\/10.1016\/j.amjmed.2010.09.012","journal-title":"Am J Med"},{"key":"4328_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2274-7","author":"XX Li","year":"2013","unstructured":"Li XX, Han M, Wang YY, Liu JP. Chinese herbal medicine for gout: a systematic review of randomized clinical trials. Clin Rheumatol. 2013. https:\/\/doi.org\/10.1007\/s10067-013-2274-7","journal-title":"Clin Rheumatol"},{"key":"4328_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s11655-014-1893-4","author":"H Luo","year":"2015","unstructured":"Luo H. Traditional tibetan medicine in China: an overview of current status and prospects. Chin J Integr Med. 2015. https:\/\/doi.org\/10.1007\/s11655-014-1893-4","journal-title":"Chin J Integr Med"},{"issue":"2","key":"4328_CR20","first-page":"326","volume":"41","author":"MR Jia","year":"2010","unstructured":"Jia MR, Zhang Y, Du J. Characteristics and sustainable development of tibetan medicine. Chin Tradit Herb Drugs. 2010;41(2):326\u201329.","journal-title":"Chin Tradit Herb Drugs"},{"issue":"28","key":"4328_CR21","first-page":"3945","volume":"27","author":"JS Chen","year":"2016","unstructured":"Chen JS, Yang QL, Liu XL, Li HN, Lin XF. Advances in chemical components, pharmacological effects and toxicology of tibetan medicine Oxytropis Falcata Bunge. China Pharm. 2016;27(28):3945\u20138.","journal-title":"China Pharm"},{"issue":"03","key":"4328_CR22","first-page":"46","volume":"35","author":"SY Yang","year":"2014","unstructured":"Yang SY, Ma WL, Dong KZ. Research progress on tibetan medicine Aconitum pendulum. J Northwest Univ Natl (Nat Sci). 2014;35(03):46\u201350.","journal-title":"J Northwest Univ Natl (Nat Sci)"},{"issue":"11","key":"4328_CR23","first-page":"4156","volume":"23","author":"ZM Li","year":"2021","unstructured":"Li ZM, Yao LL, Zou YC, Chen CY, Zhang W, Zhan ZL, et al. Advances in chemical components and pharmagological effects, and predictive analysis of quality markers of Benzoinum. Mod Tradit Chin Med Mater Med-World Sci Technol. 2021;23(11):4156\u201364.","journal-title":"Mod Tradit Chin Med Mater Med-World Sci Technol"},{"issue":"09","key":"4328_CR24","first-page":"1608","volume":"20","author":"K Zhou","year":"2018","unstructured":"Zhou K, Jian P, Liang WY, Liang LJ, Cui YP, Ye T, et al. Advances in chemical components and pharmacological effects of tibetan medicine Terminalia chebula Retz., Terminalia bellirica (Gaertn.) Roxb. And Phyllanthus emblica L. Mod Tradit Chin Med Mater Med-World Sci Technol. 2018;20(09):1608\u201314.","journal-title":"Mod Tradit Chin Med Mater Med-World Sci Technol"},{"issue":"17","key":"4328_CR25","first-page":"14","volume":"17","author":"RZM Cai","year":"2019","unstructured":"Cai RZM. Comparison of chemical components and pharmacological effects of tibetan medicines Phyllanthi Fructus and Chebulae Fructus. Contemp Med Symp. 2019;17(17):14\u20135.","journal-title":"Contemp Med Symp"},{"key":"4328_CR26","unstructured":"Zhong SH, Gu R, Wang W. Analysis of prescription and Effective Components of QiZheng QingPeng Ointment for Joint Pain. J Mil Surg Southwest Chi. 2007;(01):88\u201390."},{"issue":"12","key":"4328_CR27","first-page":"755","volume":"19","author":"JB Wang","year":"2006","unstructured":"Wang JB, Xie RA, Jiang XB, Pan L, Liang HD. Clinical investigation on the treatment of acute gouty arthritis with Qingpeng paste. Chin J Orthopa Trauma. 2006;19(12):755\u20136.","journal-title":"Chin J Orthopa Trauma"},{"issue":"33","key":"4328_CR28","first-page":"4217","volume":"20","author":"CZ Yu","year":"2011","unstructured":"Yu CZ, Xu XM, Liu X, Yan Z. Observation on the efficacy of Qingpeng ointment combined with etoricoxib in the treatment of gouty arthritis. Mod J Integr Tradit Chin and West Med. 2011;20(33):4217\u20138.","journal-title":"Mod J Integr Tradit Chin and West Med"},{"key":"4328_CR29","doi-asserted-by":"publisher","DOI":"10.14163\/j.cnki.11-5547\/r.2011.22.024","author":"QN Luo","year":"2011","unstructured":"Luo QN, Wu MQ. Contrastive study of the Qizheng Qing Peng ointment in the treatment of gouty arthritis. China Prac Med. 2011. https:\/\/doi.org\/10.14163\/j.cnki.11-5547\/r.2011.22.024","journal-title":"China Prac Med"},{"issue":"32","key":"4328_CR30","first-page":"157","volume":"49","author":"CF Lou","year":"2011","unstructured":"Lou CF. Clinical observation on 36 cases acute gouty arthritis treated with Qingpeng ointment combined diclofenac. Chin Mod Doct. 2011;49(32):157\u20138.","journal-title":"Chin Mod Doct"},{"key":"4328_CR31","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1002-7386.2011.05.083","author":"YL Liu","year":"2011","unstructured":"Liu YL. Clinical observation on the treatment of acute gouty arthritis by external application of Qingpeng ointment. Hebei Med J. 2011. https:\/\/doi.org\/10.3969\/j.issn.1002-7386.2011.05.083","journal-title":"Hebei Med J"},{"issue":"9","key":"4328_CR32","first-page":"126","volume":"7","author":"Q Jiang","year":"2017","unstructured":"Jiang Q. Clinical analysis of gout patients treated with Qingpeng ointment and etoricoxib. J Front Med. 2017;7(9):126.","journal-title":"J Front Med"},{"key":"4328_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208237","author":"T Neogi","year":"2016","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 gout classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2016. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208237","journal-title":"Ann Rheum Dis"},{"key":"4328_CR34","doi-asserted-by":"publisher","DOI":"10.16041\/j.cnki.cn15-1175.2021.09.023","author":"YY Yang","year":"2021","unstructured":"Yang YY. Efficacy of tibetan medicine Xiaotong plaster for acute gouty arthritis. J Med Parm Chin Minor. 2021. https:\/\/doi.org\/10.16041\/j.cnki.cn15-1175.2021.09.023","journal-title":"J Med Parm Chin Minor"},{"key":"4328_CR35","doi-asserted-by":"publisher","DOI":"10.7501\/j.issn.1674-5515.2018.10.038","author":"HC Wang","year":"2018","unstructured":"Wang HC, Liu J. Clinical study on Xueshan Jinluohan analgesic coating agent combined with diclofenac sodium sustained release tablets in treatment of acute gouty arthritis. Drugs Clin. 2018. https:\/\/doi.org\/10.7501\/j.issn.1674-5515.2018.10.038","journal-title":"Drugs Clin"},{"key":"4328_CR36","doi-asserted-by":"publisher","DOI":"10.16766\/j.cnki.issn.1674-4152.2011.12.010","author":"HD Liang","year":"2011","unstructured":"Liang HD, Wang JB, Pan L, Jiang XB. Clinical trial of Wuweiganlu Yaoyu Keli for acute gouty arthritis. Chin J Gen Pract. 2011. https:\/\/doi.org\/10.16766\/j.cnki.issn.1674-4152.2011.12.010","journal-title":"Chin J Gen Pract"},{"key":"4328_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2018.1505182","author":"EC Rodriguez-Merchan","year":"2018","unstructured":"Rodriguez-Merchan EC. Topical therapies for knee osteoarthritis. Postgrad Med. 2018. https:\/\/doi.org\/10.1080\/00325481.2018.1505182","journal-title":"Postgrad Med"},{"key":"4328_CR38","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2010.11.2227","author":"HR Barthel","year":"2010","unstructured":"Barthel HR, Axford-Gatley RA. Topical nonsteroidal anti-inflammatory Drugs for osteoarthritis. Postgrad Med. 2010. https:\/\/doi.org\/10.3810\/pgm.2010.11.2227","journal-title":"Postgrad Med"},{"key":"4328_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008609.pub2","author":"S Derry","year":"2017","unstructured":"Derry S, Wiffen PJ, Kalso EA, Bell RF, Aldington D, Phillips T, et al. Topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2017. https:\/\/doi.org\/10.1002\/14651858.CD008609.pub2","journal-title":"Cochrane Database Syst Rev"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-023-04328-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-023-04328-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-023-04328-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T13:03:39Z","timestamp":1704373419000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-023-04328-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4328"],"URL":"https:\/\/doi.org\/10.1186\/s12906-023-04328-7","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"26 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Fangshan Hospital, Beijing University of Chinese Medicine (FZY LK-2020\u2013015), the ethics committee of the Second Affiliated Hospital of Zhejiang Chinese Medical University (2020-Y-003-IH01), and the ethics committee of Liuzhou People\u2019s Hospital (GCP2021\u2013015\u201301). The purpose and potential risks of the trial were fully explained to all participants and their families. Every participant was asked to provide written informed consent before participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}